Drug Profile
Human fibrinogen concentrate - CSL Behring
Alternative Names: Fibrinogen Concentrate (Human); Haemocomplettan P; RiaSTAPLatest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator CSL Behring
- Developer CSL Behring; Rigshospitalet
- Class Acute-phase proteins; Antihaemorrhagics; Blood coagulation factors; Coagulants
- Mechanism of Action Fibrinogen replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Afibrinogenaemia
- Phase III Surgical blood loss
- Phase II Haemorrhage
Most Recent Events
- 28 Nov 2018 No recent reports of development identified for clinical-Phase-Unknown development in Haemorrhage(Adjunctive treatment) in United Kingdom (IV, Infusion)
- 15 Jan 2018 Yale University and CSL Behring withdraws the PERFECT PPH phase I/II trial in Postpartum haemorrhage prior to enrolment, before January 2018 (NCT02528708)
- 20 Apr 2017 CSL Behring completes a clinical trial in Haemorrhage (Adjunctive treatment) in United Kingdom (IV) (UKCRN19181)